Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31033440 | 0.86 | MEN1 (0.35) | MEN1NPC1RAB9AKMT2AOPRK1 | |
| SCHEMBL25233759 | 0.85 | MEN1 (0.41) | MEN1NPC1RAB9AKMT2AOPRK1 | |
| SCHEMBL15373732 | 0.81 | MEN1 (0.41) | MEN1NPC1RAB9AKMT2AOPRK1 | |
| SCHEMBL8247109 | 0.80 | — | — | |
| SCHEMBL22958273 | 0.80 | — | — | |
| SCHEMBL20860322 | 0.80 | — | — | |
| SCHEMBL20860351 | 0.80 | — | — | |
| SCHEMBL24521730 | 0.80 | — | — | |
| SCHEMBL23839182 | 0.80 | — | — | |
| SCHEMBL31887 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957507-B1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | IONIS PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-8569264-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114856-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20110166334-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS,INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7943749-B2 | Antimicrobial 2-deoxystreptamine compounds | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7893039-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| EP-2197835-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | Prosidion Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030962-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
| US-20080293649-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1957507-A2 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | Isis Pharmaceuticals, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080045468-A1 | ANTIMICROBIAL 2-DEOXYSTREPTAMINE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007064954-A2 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| CN-1053248-A | Inhibitor concentrate and can stablize the unsaturated thermosetting resin and the solidified product of storage | DOW CHEMICAL CO (US) | 1991-07-24 | — | — | CN | disclosed |
| US-4634701-A | Furan derivatives having anti-ulcer activity | AUSONIA FARMACEUTICI S.R.L. (IT) | 1987-01-06 | — | — | US | disclosed |
| EP-0164040-A2 | Furan derivatives having anti-ulcer activity | AUSONIA FARMACEUTICI S.r.l. (IT) | 1985-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166334-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | MEN1 3404/4885NPC1 473/4885RAB9A 1317/4885 |
| US-20080293649-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | MEN1 3404/4885NPC1 473/4885RAB9A 1317/4885 |
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | MEN1 3404/4885NPC1 473/4885RAB9A 1317/4885 |
| US-20080045468-A1 | ANTIMICROBIAL 2-DEOXYSTREPTAMINE COMPOUNDS | MTAP, UNG, PNMT | MEN1 1225/4885NPC1 415/4885RAB9A 436/4885 |
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MEN1 4874/4885NPC1 597/4885RAB9A 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.